<DOC>
	<DOCNO>NCT01028755</DOCNO>
	<brief_summary>This first time drug test human order determine safety drug , ability tolerate drug , measure drug use body result test determine maximum dose give . Specifically , follow aspect investigate : - side effect BAY79-4620 give infusion every three week - evaluation high safest dose BAY79-4620 - distribution concentration BAY79-4620 blood specific time administration - effect BAY79-4620 tumor growth - assessment `` biomarkers '' ( eg , analysis specific proteins blood sample , analysis tumor tissue sample time cancer diagnosis ) change treatment prediction safety benefit treatment BAY79-4620 .</brief_summary>
	<brief_title>To Determine Maximum Tolerated Dose BAY79-4620 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age great than/equal 18 year old . ECOG Performance Status 0 2 Life expectancy least 12 week Patients advance , histologically cytological confirm solid tumor , refractory standard therapy standard therapy available Radiographically clinically evaluable tumor Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 14 day prior start first dose : Hemoglobin &gt; 10.0 g/dL Absolute neutrophil count ( ANC ) &gt; = 1500/mm3 Platelet count &gt; = 100,000 /mm3 Total bilirubin &lt; = 1.5 time upper limit normal ALT AST &lt; = 2.5 x upper limit normal ( &lt; = 5 x upper limit normal patient liver involvement ) INR less = 1.5 PTT within normal limit ( patient undergo anticoagulative treatment , abnormal high PTT INR normal , indicating towards artificial PTT elevation cause heparinized , eligible . Serum creatinine &lt; 1.5 time upper limit normal History impair cardiac function clinically significant cardiac disease ( i.e . congestive heart failure ( CHF ) NYHA Class III IV ) ; myocardial infarction , unstable angina cardiac arrhythmia require antiarrhythmic therapy &lt; 6 month prior study entry ( beta blocker digoxin permit ) LVEF &lt; 40 % ( measure screen MUGA echocardiogram ) . Patients amylase lipase great upper limit normal range per local laboratory History pancreatitis Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mmHg , despite optimal medical management Symptomatic metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , evidence tumor growth image study within 2 week prior study entry , clinically stable respect tumor time study entry . Patients severe renal impairment dialysis Known human immunodeficiency virus ( HIV ) infection patient active hepatitis B C infection necessitate treatment . Patients chronic hepatitis B C eligible Active clinically serious infection &gt; CTCAE Grade 2 Serious , nonhealing wound , ulcer , bone fracture Known suspect allergy intolerance agent give course trial Previous cancer distinct primary site histology actual disease EXCEPT cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor [ Ta Tis ] cancer curatively treat &gt; 3 year prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Maximum Tolerated Dose</keyword>
</DOC>